

**BUY** ICICI Bank

Your success is our success

**Margin slips, but lower LLP drives strong RoA delivery**

BFSI - Banks ▶ Result Update ▶ October 22, 2023

**TARGET PRICE (Rs): 1,375**

Despite slightly higher-than-expected margin contraction by 25bps QoQ, ICICIB reported 5% earnings beat at Rs103bn/up 36% YoY (2.4% RoA), led by system-beating credit growth @18% YoY and lower provisions, as the bank has paused shoring up its already-high contingent buffer (1.2% of loans). We expect margin normalization to continue for most banks and so also for ICICIB mainly due to some moderation in unsecured loan growth amid rising stress/RBI's rebuke and continued funding cost catch-up. However, the bank's strong provisioning buffer should keep LLP lower and, thus, support its superior RoA of 2.1-2.4%/RoE of 17-19% over FY24-26E. We believe the recent stock under-performance has been mainly due to the senior mgmt.'s attrition/rejig dwarfing its otherwise strong financial performance. However, we take comfort from the strong leadership back-up at ICICIB and are hopeful the bank remains adaptive to limit the unwarranted attrition, as it aspires to build up into a "sustainable & profitable bank" in the long run. We retain BUY with a revised TP of Rs1,375 (earlier Rs1,330), rolling fwd. the core bank's valuation at 3x Sep-25E ABV (premium over HDFCB) and subsidiaries at Rs170/share.

**ICICI Bank: Financial Snapshot (Standalone)**

Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	2,33,395	3,18,965	4,07,870	4,56,426	5,06,944
Loan growth (%)	17.1	18.7	17.8	19.4	20.1
NII growth (%)	21.7	30.9	18.6	13.3	15.0
NIM (%)	3.8	4.4	4.6	4.4	4.3
PPOP growth (%)	7.8	25.1	17.6	15.3	18.8
Adj. EPS (Rs)	33.7	45.8	58.3	65.2	72.4
Adj. EPS growth (%)	39.2	36.0	27.4	11.7	11.1
Adj. BV (INR)	228.2	272.3	319.0	371.9	428.8
Adj. BVPS growth (%)	20.6	19.3	17.2	16.6	15.3
RoA (%)	1.8	2.1	2.4	2.3	2.1
RoE (%)	15.0	17.5	19.0	18.2	17.4
P/E (x)	22.7	16.7	13.1	11.7	10.5
P/ABV (x)	3.3	2.8	2.4	2.1	1.8

Source: Company, Emkay Research

**Strong growth, but margin normalization continues amid rising CoF**

ICICIB continues to outpace systemic credit growth at 18% YoY/5% QoQ and so also its largest private peer - HDFCB. Retail growth remained healthy at 22% YoY with most business segments contributing to growth and, thus, reducing dependence on unsecured loans for growth. SME growth also continued to fire up at a strong pace - up 29% YoY, which the bank has identified as a new growth engine and margin protector. Deposit growth also accelerated for the second quarter in a row at 19% YoY/5% QoQ, taking out investor concerns, though it comes with CASA ratio contracting to a low of 41%. This coupled with rising funding costs led to a 25bps margin contraction in 2Q to 4.5% (still 22bps higher YoY). We believe margins would continue to normalize due to some moderation in unsecured loans and cost catch-up.

**Strong provision buffers should protect from any stress in unsecured loans/RBI action**

Gross slippages moderated QoQ to Rs47bn/2% of loans due to moderation in retail/rural NPAs, which coupled with higher recovery/w-off led to a sharp reduction in the GNPA ratio by 28bps QoQ to 2.5%. The restructured loan book also reduced to Rs35bn/0.3% of loans, on which the bank carries 31% PCR. The FB/NFB exposure rated below BB to corporates/SME increased after long to Rs48bn/0.4% of loans in Q2FY24 from Rs43bn/0.4% of loans in Q1FY24. The bank also remains vigilant on rising stress in small-value unsecured loans, where its exposure is negligible. Specific PCR remains best among peers at 83% and, thus, leads to a lower NNPA ratio at 0.4% of loans. The bank has paused creating contingent provision buffer, which now stands at Rs131bn/1.2% of loans/Rs19 per share, again the highest among peer banks.

**Retain BUY on ICICIB, our preferred pick**


We have slightly tweaked our earnings estimates for FY24-26E by 2%, while we expect the bank to deliver superior higher RoA at 2.1-2.4%/RoE at 17-19% over FY24-26E. Notwithstanding recent underperformance, ICICIB remains our top pick in the banking space, given its superior returns profile, top-management credibility and strong capital/provision buffers amid rising stress noise. We retain BUY with a revised TP of Rs1,375/share (earlier Rs1330/share), valuing the bank at 3x Sep-25E ABV (assigning a slight premium over HDFCB) and subsidiaries at Rs170/share. Key risks: Higher middle/senior management attrition leading to business dislocation and slower-than-expected growth/margin trajectory, led by macro disruptions.

Target Price - 12M	Sep-24
<b>Change in TP (%)</b>	<b>3.4</b>
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	47.4
CMP (20-Oct-23) (Rs)	932.8

Stock Data	Ticker
52-week High (Rs)	1,009
52-week Low (Rs)	796
Shares outstanding (mn)	7,004.4
Market-cap (Rs bn)	6,533
Market-cap (USD mn)	78,601
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	17
ADTV-3M (Rs mn)	16,114.7
ADTV-3M (USD mn)	193.9
Free float (%)	100.0
Nifty-50	19,543
INR/USD	83.1
<b>Shareholding, Jun-23</b>	
Promoters (%)	-
FPIs/MFs (%)	35.9/36.5

**Price Performance**

(%)	1M	3M	12M
Absolute	(5.5)	(6.3)	5.0
Rel. to Nifty	(3.8)	(4.2)	(5.7)

**1-Year share price trend (Rs)****Anand Dama**

anand.dama@emkayglobal.com  
+91 22 6624 2480

**Kunaal N**


kunaal.n@emkayglobal.com  
+91 22 6612 1275

**Marazbaan Dastur**

marazbaan.dastur@emkayglobal.com  
+91 22 6612 1281


# Story in Charts

**Exhibit 1: Retail growth continues to push overall credit upwards**




Source: Company, Emkay Research

**Exhibit 2: Margin contraction continues amid rising CoF**




Source: Company, Emkay Research

**Exhibit 3: Credit card spending remained resilient in July-23**




Source: Company, Emkay Research

**Exhibit 4: Corporate watchlist increases after a long time**




Source: Company, Emkay Research

**Exhibit 5: Slippages were lower...**




Source: Company, Emkay Research

**Exhibit 6: ...which coupled with better recoveries and w/o led to improvement in NPA ratios**




Source: Company, Emkay Research

**Exhibit 7: Return ratios remain strong, led by healthy core profitability and lower LLP**




Source: Company, Emkay Research

**Exhibit 8: Strong core profitability led by healthy margins/fees and lower LLP to drive up RoA/RoE to a decadal high**



Source: Company, Emkay Research

**Exhibit 9: The stock is trading at 3x its one-year forward P/ABV, adj. for its subsidiary's valuation**



Source: Bloomberg, Emkay Research

**Exhibit 10: ICICI Bank's SOTP-based valuation**

ICICIB – SOTP valuation	Stake (%)	Value per share (Rs)	Basis of valuation
ICICI Standalone (A)		1196	3x Sep FY25E ABV (adj. for investments)
<b>Non-Banking Subsidiaries</b>			
ICICI Prudential Life Insurance	53%	71	2x Sep-25E EV
ICICI Lombard General Insurance	48%	53	30x Sep-25E PAT
ICICI Asset Management Company	51%	34	7% of Sep-25E AUM
ICICI Securities	75%	28	15x Sep FY25E P/E
Other Subsidiaries	100%	26	
<b>Value of Non-Banking Business</b>		<b>212</b>	
<b>Value Post Holding Co. discount (20%) (B)</b>		<b>170</b>	
<b>Value of the bank (A+B)</b>		<b>1365</b>	
Current market price		933	
<b>Upside (%)</b>		<b>47%</b>	
<b>Contribution of subs to TP (%)</b>		<b>12%</b>	

Source: Company, Emkay Research

**Exhibit 11: Actual vs. Estimates (Q2FY24)**

(Rs mn)	Actuals	Estimates		Variation (%)		Comments
		Emkay	Consensus	Emkay	Consensus	
Net income	2,40,846	2,39,478	2,41,167	1%	0%	Robust credit growth led to a beat on NII
PPOP	1,42,293	1,40,900	1,33,534	1%	7%	NII beat led to a beat on PPOP
PAT	1,02,610	97,872	98,340	5%	4%	Beat on PPOP coupled with lower provisions led to a beat on PAT

Source: Company, Emkay Research

**Exhibit 12: Quarterly Summary**

(Rs mn)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	FY23	FY24E	YoY (%)
Interest Earned	2,60,330	2,85,056	3,10,211	3,33,276	3,49,204	34	5	10,92,313	14,33,843	31
Interest Exp.	1,12,462	1,20,407	1,33,543	1,51,012	1,66,125	48	10	4,71,027	6,97,019	48
Net Interest Income	1,47,868	1,64,650	1,76,668	1,82,265	1,83,079	24	0	6,21,286	7,36,824	19
Global NIMs (reported)	4.31	4.65	4.90	4.78	4.53	22bps	-25bps	4.40	4.57	17bps
Non-interest Income	50,549	50,236	50,878	54,353	57,767	14	6	1,98,314	2,37,060	20
Operating Expenses	81,614	82,174	89,282	95,226	98,553	21	3	3,28,732	3,96,639	21
Pre Provisioning Profit	1,16,803	1,32,712	1,38,264	1,41,391	1,42,293	22	1	4,90,868	5,77,245	18
Provision & Contingencies	16,445	22,574	16,198	12,924	5,826	-65	-55	66,656	32,693	-51
PBT	1,00,358	1,10,138	1,22,066	1,28,467	1,36,466	36	6	4,24,212	5,44,552	28
Income Tax Expense (Gain)	24,780	27,019	30,847	31,985	33,856	37	6	1,05,247	1,36,683	30
Net Profit/(Loss)	75,578	83,119	91,219	96,482	1,02,610	36	6	3,18,965	4,07,870	28
Gross NPA (%)	3.19	3.07	2.81	2.76	2.48	-71bps	-28bps	2.87	2.36	-51bps
Net NPA (%)	0.61	0.55	0.48	0.48	0.43	-18bps	-5bps	0.51	0.53	2bps
Deposits (Rs bn)	10,900	11,220	11,808	12,387	12,947	19	5	11,808	13,954	18
Net Advances (Rs bn)	9,386	9,740	10,196	10,576	11,105	18	5	10,196	12,015	18

Source: Company, Emkay Research

**Exhibit 13: Revision in estimates**

Y/E March (Rs mn)	FY24E			FY25E			FY26E		
	Earlier	Revised	Change (%)	Earlier	Revised	Change (%)	Earlier	Revised	Change (%)
Net income	9,80,005	9,73,884	-0.6%	11,44,558	11,25,964	-1.6%	13,41,796	13,21,091	-1.5%
PPOP	5,76,989	5,77,245	0.0%	6,83,326	6,65,738	-2.6%	8,08,933	7,90,907	-2.2%
PAT	3,98,163	4,07,870	2.4%	4,58,450	4,56,426	-0.4%	5,16,943	5,06,944	-1.9%
EPS (Rs)	57.0	58.3	2.4%	65.5	65.2	-0.5%	73.9	72.4	-2.0%
BV (Rs)	331.4	331.4	0.0%	387.9	386.6	-0.3%	451.7	447.0	-1.1%

Source: Emkay Research

**Exhibit 14: Key Assumptions**

(%)	FY23A	FY24E	FY25E	FY26E
Loan Growth (%)	18.7	17.8	19.4	20.1
Deposit Growth (%)	10.9	18.2	19.1	20.2
NIM (%)	4.4	4.6	4.4	4.3
GNPA (%)	2.9	2.4	2.1	2.1
Credit Cost (%)	(0.1)	0.4	0.5	0.7
Yield on Advances	9.0	10.0	9.7	9.4
Cost of Deposits	3.5	4.7	4.6	4.4

Source: Emkay Research

## Exhibit 15: Key ratios and trends

	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24
Loans (Rs mn)	76,49,374	81,39,916	85,90,204	89,56,248	93,85,628	97,40,475	101,96,383	105,75,826	111,05,421
growth (YoY)	17.2	16.4	17.1	21.3	22.7	19.7	18.7	18.1	18.3

## Composition (%)

- Corporate - Domestic	23	24	23	23	23	23	23	23	22
- Overseas	5	5	5	5	4	4	3	3	3
- SME	4	4	5	4	4	5	5	5	5
- Retail + Rural + BB	68	68	68	68	69	70	70	71	71
- Retail	52	53	53	53	54	54	55	55	55
- Rural	9	9	9	9	9	9	9	9	8
- Business Banking	6	6	6	6	7	7	7	7	7

Deposit (Rs mn)	97,74,486	101,74,667	106,45,716	105,03,490	109,00,080	112,20,495	118,08,407	123,87,366	129,47,417
growth (YoY)	17.4	16.4	14.2	13.4	11.5	10.3	10.9	17.9	18.8
CASA (%)	46.1	47.2	48.7	46.9	46.6	45.3	45.8	43.3	40.8
CA (%)	13.5	14.4	14.9	13.4	13.3	13.0	13.7	13.0	12.0
SA (%)	32.6	32.9	33.8	33.5	33.3	32.4	32.2	30.3	28.8

## Asset Quality / Capital

GNPA (%)	4.8	4.1	3.6	3.4	3.2	3.1	2.8	2.8	2.5
NNPA (%)	1.0	0.9	0.8	0.7	0.6	0.6	0.5	0.5	0.4
PCR (%)	80.3	80.2	79.5	79.9	81.3	82.6	83.5	83.1	82.6
Slippages (Rs mn)	55,780	40,180	42,040	58,250	43,660	57,230	42,970	53,180	46,870
Slippages (%)	3.4	2.3	2.3	3.2	2.3	2.8	2.0	2.4	2.0
Restructured loans (% of loans)	1.3	1.2	1.0	0.8	0.7	0.5	0.4	0.4	0.3
CAR (%)	18.3	19.4	19.2	18.0	16.9	16.3	18.3	16.7	17.6
Tier I (%)	17.3	18.4	18.4	17.3	16.2	15.5	17.6	16.0	16.9

## ROE Decomposition (%)

NII	3.7	3.7	3.6	3.7	4.1	4.4	4.6	4.5	4.3
Other Income (Ex Treasury)	1.4	1.5	1.3	1.3	1.4	1.3	1.3	1.3	1.4
Treasury	0.1	0.0	0.0	0.0	(0.0)	0.0	(0.0)	0.1	(0.0)
Opex	2.1	2.2	2.0	2.1	2.2	2.2	2.3	2.4	2.3
PPOP	3.2	3.1	3.0	2.9	3.2	3.5	3.6	3.5	3.4
Provisions	0.9	0.6	0.3	0.3	0.5	0.6	0.4	0.3	0.1
PBT	2.3	2.5	2.7	2.6	2.8	2.9	3.1	3.2	3.2
Tax	0.5	0.6	0.6	0.6	0.7	0.7	0.8	0.8	0.8
ROA	1.8	1.9	2.0	2.0	2.1	2.2	2.3	2.4	2.4
ROE	14.3	15.5	16.8	15.9	16.8	17.8	18.6	18.7	19.2

Source: Company, Emkay Research

## ICICI Bank: Standalone Financials and Valuations

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	8,63,745	10,92,313	14,33,843	16,29,443	18,75,377
Interest Expense	3,89,085	4,71,027	6,97,019	7,94,818	9,15,762
<b>Net interest income</b>	<b>4,74,661</b>	<b>6,21,286</b>	<b>7,36,824</b>	<b>8,34,625</b>	<b>9,59,615</b>
NII growth (%)	21.7	30.9	18.6	13.3	15.0
Other income	1,85,175	1,98,314	2,37,060	2,91,339	3,61,476
<b>Total Income</b>	<b>6,59,836</b>	<b>8,19,600</b>	<b>9,73,884</b>	<b>11,25,964</b>	<b>13,21,091</b>
Operating expenses	2,67,333	3,28,732	3,96,639	4,60,226	5,30,184
<b>PPOP</b>	<b>3,92,503</b>	<b>4,90,868</b>	<b>5,77,245</b>	<b>6,65,738</b>	<b>7,90,907</b>
PPOP growth (%)	7.8	25.1	17.6	15.3	18.8
<b>Core PPOP</b>	<b>3,85,477</b>	<b>4,90,427</b>	<b>5,66,115</b>	<b>6,43,478</b>	<b>7,57,517</b>
Provisions & contingencies	86,414	66,656	32,693	56,358	1,14,079
<b>PBT</b>	<b>3,06,089</b>	<b>4,24,212</b>	<b>5,44,552</b>	<b>6,09,380</b>	<b>6,76,828</b>
Extraordinary items	0	0	0	0	0
Tax expense	72,694	1,05,247	1,36,683	1,52,954	1,69,884
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>2,33,395</b>	<b>3,18,965</b>	<b>4,07,870</b>	<b>4,56,426</b>	<b>5,06,944</b>
PAT growth (%)	44.1	36.7	27.9	11.9	11.1
<b>Adjusted PAT</b>	<b>2,33,395</b>	<b>3,18,965</b>	<b>4,07,870</b>	<b>4,56,426</b>	<b>5,06,944</b>
<b>Diluted EPS (Rs)</b>	<b>33.5</b>	<b>45.6</b>	<b>58.1</b>	<b>64.9</b>	<b>72.1</b>
Diluted EPS growth (%)	39.2	36.0	27.4	11.7	11.1
<b>DPS (Rs)</b>	<b>5.0</b>	<b>8.0</b>	<b>9.0</b>	<b>10.0</b>	<b>12.0</b>
<b>Dividend payout (%)</b>	<b>14.9</b>	<b>17.5</b>	<b>15.5</b>	<b>15.3</b>	<b>33.9</b>
Effective tax rate (%)	23.7	24.8	25.1	25.1	25.1
Net interest margins (%)	3.8	4.4	4.6	4.4	4.3
Cost-income ratio (%)	40.5	40.1	40.7	40.9	40.1
Shares outstanding (mn)	6,949.9	6,983.9	7,004.2	7,004.2	7,004.2

Source: Company, Emkay Research

Asset Quality and Other Metrics					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
<b>Asset quality</b>					
Gross NPLs	3,32,949.2	2,99,860.7	2,89,455.7	3,02,201.8	3,66,879.7
Net NPLs	69,310.4	51,500.7	63,680.2	81,594.5	1,10,063.9
GNPA ratio (%)	3.8	2.9	2.4	2.1	2.1
NNPA ratio (%)	0.8	0.5	0.5	0.6	0.6
Provision coverage (%)	79.2	82.8	78.0	73.0	70.0
Gross slippages	1,92,910.1	1,83,093.8	2,08,101.1	2,54,923.8	3,23,389.0
Gross slippage ratio (%)	2.2	1.8	1.7	1.8	1.9
LLP ratio (%)	0.7	(0.1)	0.4	0.5	0.7
NNPA to networth (%)	3.9	2.4	2.5	2.8	3.3
<b>Capital adequacy</b>					
Total CAR (%)	19.2	18.3	18.2	17.9	17.4
Tier-1 (%)	18.3	17.6	17.3	17.1	16.6
CET-1 (%)	17.6	17.1	16.9	16.8	16.3
RWA-to-Total Assets (%)	62.6	67.6	70.0	70.0	70.0
<b>Miscellaneous</b>					
Total income growth (%)	6.9	23.0	29.5	15.0	16.5
Opex growth (%)	24.0	23.0	20.7	16.0	15.2
Core PPOP growth (%)	23.5	27.2	15.4	13.7	17.7
PPOP margin (%)	37.4	38.0	34.5	34.7	35.4
PAT/PPOP (%)	59.5	65.0	70.7	68.6	64.1
LLP-to-Core PPOP (%)	22.4	13.6	5.8	8.8	15.1
Yield on advances (%)	8.1	9.0	10.0	9.7	9.4
Cost of funds (%)	3.5	3.8	4.9	4.7	4.6

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	13,900	13,968	14,008	14,008	14,008
Reserves & surplus	16,91,220	19,93,186	23,35,186	27,18,694	31,38,687
<b>Net worth</b>	<b>17,05,120</b>	<b>20,07,154</b>	<b>23,49,194</b>	<b>27,32,702</b>	<b>31,52,695</b>
Deposits	106,45,716	118,08,407	139,54,116	166,21,090	199,86,223
Borrowings	10,72,314	11,93,255	13,96,967	16,23,736	19,44,782
<b>Interest-bearing liab.</b>	<b>117,18,030</b>	<b>130,01,662</b>	<b>153,51,083</b>	<b>182,44,826</b>	<b>219,31,005</b>
<b>Other liabilities &amp; prov.</b>	<b>6,89,828</b>	<b>8,33,252</b>	<b>7,02,530</b>	<b>8,15,764</b>	<b>9,57,791</b>
<b>Total liabilities &amp; equity</b>	<b>141,12,977</b>	<b>158,42,067</b>	<b>184,02,808</b>	<b>217,93,291</b>	<b>260,41,491</b>
Net advances	85,90,204	101,96,383	120,15,463	143,46,467	172,23,673
Investments	31,02,410	36,23,297	41,29,394	47,71,137	56,26,629
Cash, other balances	16,78,224	11,94,383	12,28,087	14,59,586	17,54,480
<b>Interest-earning assets</b>	<b>133,70,838</b>	<b>150,14,063</b>	<b>173,72,944</b>	<b>205,77,190</b>	<b>246,04,783</b>
Fixed assets	93,738	95,998	1,06,607	1,17,267	1,28,994
Other assets	6,48,401	7,32,005	9,23,257	10,98,834	13,07,714
<b>Total assets</b>	<b>141,12,977</b>	<b>158,42,067</b>	<b>184,02,808</b>	<b>217,93,291</b>	<b>260,41,491</b>
BVPS (Rs)	241.3	283.7	331.9	386.6	447.0
Adj. BVPS (INR)	234.7	278.8	325.9	378.9	436.6
Gross advances	88,53,843	104,44,743	122,41,239	145,67,074	174,80,489
Credit to deposit (%)	80.7	86.3	86.1	86.3	86.2
CASA ratio (%)	48.7	45.8	40.4	39.0	38.6
Cost of deposits (%)	3.3	3.5	4.7	4.6	4.4
Loans-to-Assets (%)	60.9	64.4	65.3	65.8	66.1
Net advances growth (%)	17.1	18.7	17.8	19.4	20.1
Deposit growth (%)	14.2	10.9	18.2	19.1	20.2
Book value growth (%)	11.9	17.6	17.0	16.5	15.6

Source: Company, Emkay Research

Valuations and Key Ratios					
Y/E March	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	22.7	16.7	13.1	11.7	10.5
P/B (x)	3.2	2.7	2.3	2.0	1.7
P/ABV (x)	3.2	2.7	2.3	2.0	1.7
P/PPOP (x)	16.5	13.2	11.3	9.8	8.2
Dividend yield (%)	0.5	0.9	1.0	1.1	1.3
<b>DuPont-RoE split (%)</b>					
NII/avg assets	3.6	4.1	4.3	4.2	4.0
Other income	1.4	1.3	1.4	1.4	1.5
Fee income	1.0	1.0	1.0	1.1	1.1
Opex	2.0	2.2	2.3	2.3	2.2
<b>PPOP</b>	<b>3.0</b>	<b>3.3</b>	<b>3.4</b>	<b>3.3</b>	<b>3.3</b>
Core PPOP	2.9	3.3	3.3	3.2	3.2
Provisions	0.7	0.4	0.2	0.3	0.5
Tax expense	0.6	0.7	0.8	0.8	0.7
<b>RoA (%)</b>	<b>1.8</b>	<b>2.1</b>	<b>2.4</b>	<b>2.3</b>	<b>2.1</b>
Leverage ratio (x)	8.5	8.2	8.0	8.0	8.2
<b>RoE (%)</b>	<b>15.0</b>	<b>17.5</b>	<b>19.0</b>	<b>18.2</b>	<b>17.4</b>
<b>Quarterly data</b>					
Rs mn, Y/E March	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24
NII	1,47,868	1,64,650	1,76,668	1,82,265	1,83,079
NIM (%)	4.3	4.7	4.9	4.8	4.5
PPOP	1,16,803	1,32,712	1,38,264	1,41,391	1,42,293
PAT	75,578	83,119	91,219	96,482	1,02,610
EPS (Rs)	10.85	11.91	13.06	13.79	14.66


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	CMP (INR)	TP (INR)	Rating	Analyst
23-Jul-23	997	1,330	Buy	Anand Dama
13-Jul-23	956	1,250	Buy	Anand Dama
24-Apr-23	905	1,250	Buy	Anand Dama
09-Mar-23	856	1,250	Buy	Anand Dama
22-Jan-23	870	1,250	Buy	Anand Dama
04-Dec-22	931	1,225	Buy	Anand Dama
24-Oct-22	926	1,170	Buy	Anand Dama
24-Jul-22	800	1,025	Buy	Anand Dama
24-Apr-22	748	1,025	Buy	Anand Dama
23-Jan-22	805	1,025	Buy	Anand Dama
04-Dec-21	716	950	Buy	Anand Dama
24-Oct-21	759	950	Buy	Anand Dama
25-Aug-21	691	825	Buy	Anand Dama
25-Jul-21	677	825	Buy	Anand Dama
25-Apr-21	570	730	Buy	Anand Dama
31-Jan-21	537	700	Buy	Anand Dama
20-Jan-21	551	700	Buy	Anand Dama
06-Dec-20	502	600	Buy	Anand Dama
01-Nov-20	393	520	Buy	Anand Dama

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.



**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of October 22, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of October 22, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 22, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	Over 15%
<b>HOLD</b>	Between -5% to 15%
<b>SELL</b>	Below -5%

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.